Literature DB >> 7881744

Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine.

M E Benwell1, D J Balfour, C E Birrell.   

Abstract

1. The effects of constant nicotine infusions (0.25, 1.0 and 4.0 mg kg-1 day-1) on extracellular dopamine levels in the nucleus accumbens (NAc) and on locomotor activity have been compared with the changes evoked by repeated daily injections (0.4 mg kg-1 day-1 for 5 days) of the drug. 2. The extracellular dopamine concentration in the NAc was significantly increased (P < 0.05) following a challenge dose of nicotine (0.4 mg kg-1, s.c.) in animals which had been pretreated with daily injections of the drug. This effect was accompanied by an enhanced locomotor response to nicotine. 3. The stimulant effects of nicotine on mesolimbic dopamine secretion and on locomotor activity were significantly inhibited (P < 0.01) by the prior administration of mecamylamine (2.0 mg kg-1, s.c.) but not by hexamethonium (2.0 mg kg-1, s.c.). 4. The constant infusion of nicotine at a rate of 1 and 4 but not 0.25 mg kg-1 day-1 abolished the sensitized dopamine response in the NAc to an injection of nicotine in animals pretreated with the drug. The locomotor responses to nicotine in the nicotine-pretreated rats were significantly attenuated by the infusion of nicotine at all 3 doses, although the nicotine induced locomotor activity, in the rats infused with 0.25 mg kg-1 day-1 was also significantly (P < 0.05) higher than that observed in the rats treated acutely with nicotine. 5. Significantly (P<0.01) enhanced mesolimbic dopamine responses, to a challenge injection of nicotine(0.4 mg kg-1, s.c.), were observed 2 and 7 days after termination of the infusion of nicotine (4 mg kg-1 day-1 for 14 days); locomotor responses were enhanced (P<0.01) 1, 2 and 7 days after termination of the infusion.6. The results suggest that sensitized mesolimbic dopamine responses to nicotine occur as a result of stimulation of centrally located nicotinic receptors but that these receptors may be desensitized during periods of chronic exposure to nicotine at doses which may be relevant to smoking.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7881744      PMCID: PMC1510263          DOI: 10.1111/j.1476-5381.1995.tb13248.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection.

Authors:  A M Janson; K Fuxe; L F Agnati; I Kitayama; A Härfstrand; K Andersson; M Goldstein
Journal:  Brain Res       Date:  1988-07-12       Impact factor: 3.252

2.  Cardiovascular and subjective effects of smoking before and after 24 h of abstinence from cigarettes.

Authors:  R J West; M A Russell
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase.

Authors:  M Naoi; Y Nomura; R Ishiki; H Suzuki; T Nagatsu
Journal:  J Neurochem       Date:  1988-01       Impact factor: 5.372

4.  Aversive environmental stimuli as a factor in the psychostimulant response to nicotine.

Authors:  A L Vale; D J Balfour
Journal:  Pharmacol Biochem Behav       Date:  1989-04       Impact factor: 3.533

5.  Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats.

Authors:  A Imperato; A Mulas; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1986-12-16       Impact factor: 4.432

6.  Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

7.  Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens.

Authors:  G Damsma; J Day; H C Fibiger
Journal:  Eur J Pharmacol       Date:  1989-09-22       Impact factor: 4.432

8.  Effects of chronic nicotine pretreatment on (+)-amphetamine and nicotine-induced synthesis and release of [3H]dopamine from [3H]tyrosine in rat nucleus accumbens.

Authors:  Y K Fung
Journal:  J Pharm Pharmacol       Date:  1989-01       Impact factor: 3.765

9.  Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats.

Authors:  P B Clarke; D S Fu; A Jakubovic; H C Fibiger
Journal:  J Pharmacol Exp Ther       Date:  1988-08       Impact factor: 4.030

10.  Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain.

Authors:  D G Kirch; G A Gerhardt; R C Shelton; R Freedman; R J Wyatt
Journal:  Clin Neuropharmacol       Date:  1987-08       Impact factor: 1.592

View more
  47 in total

1.  Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats.

Authors:  Neil E Paterson; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

2.  Deficits in a sustained attention task following nicotine withdrawal in rats.

Authors:  Mohammed Shoaib; Lisiane Bizarro
Journal:  Psychopharmacology (Berl)       Date:  2004-08-27       Impact factor: 4.530

3.  Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.

Authors:  Salma R I Ribeiz; Débora P Bassitt; Jony A Arrais; Renata Avila; David C Steffens; Cássio M C Bottino
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

4.  Differential control of central cardiorespiratory interactions by hypercapnia and the effect of prenatal nicotine.

Authors:  Zheng-Gui Huang; Kathleen J S Griffioen; Xin Wang; Olga Dergacheva; Harriet Kamendi; Christopher Gorini; Euguenia Bouairi; David Mendelowitz
Journal:  J Neurosci       Date:  2006-01-04       Impact factor: 6.167

5.  Ventral striatum/nucleus accumbens activation to smoking-related pictorial cues in smokers and nonsmokers: a functional magnetic resonance imaging study.

Authors:  Sean P David; Marcus R Munafò; Heidi Johansen-Berg; Stephen M Smith; Robert D Rogers; Paul M Matthews; Robert T Walton
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

6.  Nicotine and Resting-State Functional Connectivity: Effects of Intermittent Doses.

Authors:  Wei Huang; Kelly Tam; Janaque Fernando; Meghan Heffernan; Jean King; Joseph R DiFranza
Journal:  Nicotine Tob Res       Date:  2015-02-02       Impact factor: 4.244

7.  Chronic intermittent nicotine delivery via lung alveolar region-targeted aerosol technology produces circadian pharmacokinetics in rats resembling human smokers.

Authors:  Xuesi M Shao; Siyu Liu; Eon S Lee; David Fung; Hua Pei; Jing Liang; Ross Mudgway; Jingxi Zhang; Jack L Feldman; Yifang Zhu; Stan Louie; Xinmin S Xie
Journal:  J Appl Physiol (1985)       Date:  2018-09-20

8.  A novel method to induce nicotine dependence by intermittent drug delivery using osmotic minipumps.

Authors:  Julia K Brynildsen; Julie Najar; Li-Ming Hsu; D Bruce Vaupel; Hanbing Lu; Thomas J Ross; Yihong Yang; Elliot A Stein
Journal:  Pharmacol Biochem Behav       Date:  2016-01-02       Impact factor: 3.533

9.  Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.

Authors:  B Buisson; D Bertrand
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

10.  Neurochemical and behavioural interactions between ibogaine and nicotine in the rat.

Authors:  M E Benwell; P E Holtom; R J Moran; D J Balfour
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.